Soligenix To Test Synthetic Hypericin In Psoriasis Patients

Soligenix Inc SNGX says that following the validation of synthetic hypericin's biologic activity, the Company will be expanding the therapy under the research name SGX302 into psoriasis.
Related Content: Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate.
Visible light-activated synthetic hypericin is a photodynamic therapy (PDT) that is expected to avoid much of the long-term risks associated with other PDT treatments.
Synthetic hypericin is a potent photosensitizer topically applied to skin lesions and taken up by cutaneous T-cells.
The use of visible light in the red-yellow spectrum has the advantage of deeper penetration into the skin, potentially treating deeper skin disease and thicker plaques and lesions.
The Company plans to start enrollment in the latter part of 2022.
Price Action: SNGX stock is down 5.91% at $1.04 during the market session on the last check Thursday.